Public Profile

2seventy bio, Inc.

2seventy bio, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing transformative cell therapies for cancer treatment. Founded in 2020, the company has quickly established itself in the biopharmaceutical industry, particularly in the areas of engineered cell therapies and innovative drug development. With a commitment to advancing the field of oncology, 2seventy bio's core offerings include cutting-edge therapies that harness the power of the immune system to target and eliminate cancer cells. Their unique approach combines scientific expertise with a patient-centric focus, setting them apart in a competitive market. Recognised for its rapid progress and innovative solutions, 2seventy bio is positioned as a leader in the fight against cancer, striving to improve patient outcomes and redefine treatment paradigms.

DitchCarbon Score

How does 2seventy bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

2seventy bio, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

52%

2seventy bio, Inc.'s reported carbon emissions

2seventy bio, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for recent years, nor specific reduction targets or climate commitments outlined in their initiatives. Without concrete figures or defined goals, it is challenging to assess their carbon footprint or climate strategy. However, the absence of emissions data suggests a potential opportunity for the company to establish and communicate its environmental commitments more clearly. As the biotechnology industry increasingly prioritises sustainability, 2seventy bio may benefit from developing measurable targets and transparent reporting to align with industry standards and stakeholder expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. 2seventy bio, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. 2seventy bio, Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

2seventy bio, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Was this information valuable to you?

Similar Organizations

TG Therapeutics, Inc.

US
Chemicals nec
Updated about 1 month ago

Sanofi SA

CH
Chemicals nec
Updated 2 months ago
DitchCarbon Score

Pfizer

US
Medical, precision and optical instruments, watches and clocks (33)
Updated about 2 hours ago

Genmab

DK
Medical, precision and optical instruments, watches and clocks (33)
Updated 26 days ago

Precigen, Inc.

US
Health and social work services (85)
Updated about 1 month ago

Bms

US
Chemicals nec
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers